spacer gif spacer gif spacer gif spacer gif spacer gif
QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search    

The fully linked HTML version of this article has now been published.
JCS ePress online publication date 15 Aug 2006
doi: 10.1242/jcs.03145

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jcs.03145v1
119/17/3664    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Girdler, F.
Right arrow Articles by Taylor, S. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Girdler, F.
Right arrow Articles by Taylor, S. S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Research Article

Validating Aurora B as an anti-cancer drug target


Fiona Girdler, Karen E. Gascoigne, Patrick A. Eyers, Sonya Hartmuth, Claire Crafter, Kevin M. Foote, Nicholas J. Keen, and Stephen S. Taylor*
* Author for correspondence (e-mail: stephen.taylor{at}manchester.ac.uk)

The Aurora kinases, a family of mitotic regulators, have received much attention as potential targets for novel anti-cancer therapeutics. Several Aurora kinase inhibitors have been described including ZM447439, which prevents chromosome alignment, spindle checkpoint function and cytokinesis. Subsequently, ZM447439-treated cells exit mitosis without dividing and lose viability. Because ZM447439 inhibits both Aurora A and B, we set out to determine which phenotypes are due to inhibition of which kinase. Using molecular genetic approaches, we show that inhibition of Aurora B kinase activity phenocopies ZM447439. Furthermore, a novel ZM compound, which is 100 times more selective for Aurora B over Aurora A in vitro, induces identical phenotypes. Importantly, inhibition of Aurora B kinase activity induces a penetrant anti-proliferative phenotype, indicating that Aurora B is an attractive anti-cancer drug target. Using molecular genetic and chemical-genetic approaches, we also probe the role of Aurora A kinase activity. We show that simultaneous repression of Aurora A plus induction of a catalytic mutant induces a monopolar phenotype. Consistently, another novel ZM-related inhibitor, which is 20 times as potent against Aurora A compared with ZM447439, induces a monopolar phenotype. Expression of a drug-resistant Aurora A mutant reverts this phenotype, demonstrating that Aurora A kinase activity is required for spindle bipolarity in human cells. Because small molecule-mediated inhibition of Aurora A and Aurora B yields distinct phenotypes, our observations indicate that the Auroras may present two avenues for anti-cancer drug discovery.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCBHome page
L. L. Hall, M. Byron, G. Pageau, and J. B. Lawrence
AURKB-mediated effects on chromatin regulate binding versus release of XIST RNA to the inactive chromosome
J. Cell Biol., August 24, 2009; 186(4): 491 - 507.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. S. Boss, J. H. Beijnen, and J. H.M. Schellens
Clinical Experience with Aurora Kinase Inhibitors: A Review
Oncologist, August 1, 2009; 14(8): 780 - 793.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Kaestner, A. Stolz, and H. Bastians
Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells
Mol. Cancer Ther., July 1, 2009; 8(7): 2046 - 2056.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. J. Scutt, M. L. H. Chu, D. A. Sloane, M. Cherry, C. R. Bignell, D. H. Williams, and P. A. Eyers
Discovery and Exploitation of Inhibitor-resistant Aurora and Polo Kinase Mutants for the Analysis of Mitotic Networks
J. Biol. Chem., June 5, 2009; 284(23): 15880 - 15893.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A.-L. Salmela, J. Pouwels, A. Varis, A. M. Kukkonen, P. Toivonen, P. K. Halonen, M. Perala, O. Kallioniemi, G. J. Gorbsky, and M. J. Kallio
Dietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpoint
Carcinogenesis, June 1, 2009; 30(6): 1032 - 1040.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Oke, D. Pearce, R. W. Wilkinson, C. Crafter, R. Odedra, J. Cavenagh, J. Fitzgibbon, A. T. Lister, S. Joel, and D. Bonnet
AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo
Cancer Res., May 15, 2009; 69(10): 4150 - 4158.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Hose, T. Reme, T. Meissner, J. Moreaux, A. Seckinger, J. Lewis, V. Benes, A. Benner, M. Hundemer, T. Hielscher, et al.
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
Blood, April 30, 2009; 113(18): 4331 - 4340.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. C. VanderPorten, P. Taverna, J. N. Hogan, M. D. Ballinger, W. M. Flanagan, and R. V. Fucini
The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model
Mol. Cancer Ther., April 1, 2009; 8(4): 930 - 939.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
D. O. Cowley, J. A. Rivera-Perez, M. Schliekelman, Y. J. He, T. G. Oliver, L. Lu, R. O'Quinn, E. D. Salmon, T. Magnuson, and T. Van Dyke
Aurora-A Kinase Is Essential for Bipolar Spindle Formation and Early Development
Mol. Cell. Biol., February 15, 2009; 29(4): 1059 - 1071.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. B. Mistry, D. E. MacCallum, R. C. Jackson, M. A. J. Chaplain, and F. A. Davidson
Modeling the temporal evolution of the spindle assembly checkpoint and role of Aurora B kinase
PNAS, December 23, 2008; 105(51): 20215 - 20220.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. G. Lin, A. Immaneni, W. M. Merritt, L. S. Mangala, S. W. Kim, M. M.K. Shahzad, Y. T.M. Tsang, G. N. Armaiz-Pena, C. Lu, A. A. Kamat, et al.
Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth
Clin. Cancer Res., September 1, 2008; 14(17): 5437 - 5446.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
J. E. Swain, J. Ding, J. Wu, and G. D. Smith
Regulation of spindle and chromatin dynamics during early and late stages of oocyte maturation by aurora kinases
Mol. Hum. Reprod., May 1, 2008; 14(5): 291 - 299.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. M. D'Alise, G. Amabile, M. Iovino, F. P. Di Giorgio, M. Bartiromo, F. Sessa, F. Villa, A. Musacchio, and R. Cortese
Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells
Mol. Cancer Ther., May 1, 2008; 7(5): 1140 - 1149.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
E. Walsby, V. Walsh, C. Pepper, A. Burnett, and K. Mills
Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts
Haematologica, May 1, 2008; 93(5): 662 - 669.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Gautschi, J. Heighway, P. C. Mack, P. R. Purnell, P. N. Lara Jr., and D. R. Gandara
Aurora Kinases as Anticancer Drug Targets
Clin. Cancer Res., March 15, 2008; 14(6): 1639 - 1648.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
A. R. Barr and F. Gergely
Aurora-A: the maker and breaker of spindle poles
J. Cell Sci., September 1, 2007; 120(17): 2987 - 2996.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
K. Hoar, A. Chakravarty, C. Rabino, D. Wysong, D. Bowman, N. Roy, and J. A. Ecsedy
MLN8054, a Small-Molecule Inhibitor of Aurora A, Causes Spindle Pole and Chromosome Congression Defects Leading to Aneuploidy
Mol. Cell. Biol., June 15, 2007; 27(12): 4513 - 4525.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. J. LeRoy, J. J. Hunter, K. M. Hoar, K. E. Burke, V. Shinde, J. Ruan, D. Bowman, K. Galvin, and J. A. Ecsedy
Localization of Human TACC3 to Mitotic Spindles Is Mediated by Phosphorylation on Ser558 by Aurora A: A Novel Pharmacodynamic Method for Measuring Aurora A Activity
Cancer Res., June 1, 2007; 67(11): 5362 - 5370.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
B. T. Keady, P. Kuo, S. E. Martinez, L. Yuan, and L. E. Hake
MAPK interacts with XGef and is required for CPEB activation during meiosis in Xenopus oocytes
J. Cell Sci., March 15, 2007; 120(6): 1093 - 1103.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. G. Manfredi, J. A. Ecsedy, K. A. Meetze, S. K. Balani, O. Burenkova, W. Chen, K. M. Galvin, K. M. Hoar, J. J. Huck, P. J. LeRoy, et al.
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase
PNAS, March 6, 2007; 104(10): 4106 - 4111.
[Abstract] [Full Text] [PDF]


© The Company of Biologists Ltd 2006